PAHC has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PAHC has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
As of today, Phibro Animal Health's Trailing 12-Month Free Cash Flow is $41 Mil, and Market Cap is $918 Mil. Therefore, Phibro Animal Health's FCF Yield % for today is 4.43%.
The historical rank and industry rank for Phibro Animal Health's FCF Yield % or its related term are showing as below:
During the past 13 years, the highest FCF Yield % of Phibro Animal Health was 8.60%. The lowest was -10.88%. And the median was 2.26%.
Phibro Animal Health's FCF Margin % for the quarter that ended in Sep. 2024 was 1.17%.
The historical data trend for Phibro Animal Health's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Phibro Animal Health Annual Data | |||||||||||||||||||||
Trend | Jun15 | Jun16 | Jun17 | Jun18 | Jun19 | Jun20 | Jun21 | Jun22 | Jun23 | Jun24 | |||||||||||
FCF Yield % | Get a 7-Day Free Trial | 2.38 | 1.62 | -0.70 | -6.94 | 6.82 |
Phibro Animal Health Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
FCF Yield % | Get a 7-Day Free Trial | 6.75 | 17.57 | 1.28 | 9.04 | 1.33 |
For the Drug Manufacturers - Specialty & Generic subindustry, Phibro Animal Health's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Phibro Animal Health's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Phibro Animal Health's FCF Yield % falls into.
FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Phibro Animal Health's FCF Yield % for the fiscal year that ended in Jun. 2024 is calculated as
FCF Yield % | = | Free Cash Flow | / | Market Cap |
= | 46.356 | / | 679.245372 | |
= | 6.82% |
Phibro Animal Health's annualized FCF Yield % for the quarter that ended in Sep. 2024 is calculated as
FCF Yield % | = | Free Cash Flow | * | Annualized Factor | / | Market Cap |
= | 3.039 | * | 4 | / | 912.141072 | |
= | 1.33% |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Phibro Animal Health FCF Yield % Explanation
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Thank you for viewing the detailed overview of Phibro Animal Health's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.
E Thomas Corcoran | director | |
Judith Weinstein | officer: See Remarks | C/O PHIBRO ANIMAL HEALTH CORP, 300 FRANK W. BURR BOULEVARD, STE 21, TEANECK NJ 07666 |
Alejandro Bernal | director | C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054 |
Larry Lee Miller | officer: Chief Operating Officer | 8 HAZELWOOD COURT, WARREN NJ 07059 |
Damian Finio | officer: Chief Financial Officer | C/O IGI LABORATORIES, INC., 105 LINCOLN AVENUE, BUENA NJ 08310 |
Robin Aukerman | officer: President,North America Region | C/O PHIBRO, GLENPOINTE CENTRE EAST, 3RD FL, 300 FRANK W. BURR BLVD, STE 21, TEANECK NJ 07666 |
Daniel M Bendheim | director, officer: Exec. VP, Corporate Strategy | 300 FRANK W. BURR BOULEVARD, SUITE 21, TEANECK NJ 07666 |
Dean J Warras | officer: Pres Animal Health & Nutr N.A. | 5113 SPYGLASS HILL, QUINCY IL 62305 |
Jack Bendheim | director, 10 percent owner, officer: President and CEO | C/O EMPIRE RESOURCES, INC., 1 PARKER PLAZA, SUIET 10, FORT LEE NJ 07024 |
Bfi Co., Llc | 10 percent owner | 300 FRANK W. BURR BLVD., STE 21, TEANECK NJ 07666 |
Jonathan Bendheim | director | GLENPOINTE CENTRE EAST, 3RD FLOOR, 300 FRANK W. BURR BLVD. SUITE 21, TEANECK NJ 07666 |
Anthony Andolino | officer: SEE REMARKS | GLENPOINTE CENTRE EAST, 3RD FLOOR, 300 FRANK W. BURR BLVD., STE 21, TEANECK NJ 07666 |
Richard G Johnson | officer: Chief Financial Officer | 7 WEST 96TH STREET, APT. 11C, NEW YORK NY 10025 |
Gerald K Carlson | director | 2496 OLD BEACH ROAD, WAYZATA MN 55391 |
Thomas G Dagger | officer: SVP, Gen Counsel and Corp Sec | 41 WILCOX DRIVE, MOUNTAIN LAKES NJ 07046 |
From GuruFocus
By GuruFocus Research • 05-10-2024
By GuruFocus News • 10-09-2024
By Business Wire • 08-28-2024
By GuruFocus News • 11-06-2024
By Business Wire • 08-29-2024
By GuruFocus Research • 09-06-2024
By Business Wire • 08-14-2024
By GuruFocus News • 10-08-2024
By GuruFocus Research • 09-12-2024
By GuruFocus Research • 08-28-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.